Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 46.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 23.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of IRIDEX was 46.20% per year. The lowest was -181.70% per year. And the median was 1.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
IRIDEX 5-Year EBITDA Growth Rate Related Terms
IRIX vs ICCM, LFWD, GTHP: 5-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, IRIDEX's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IRIDEX 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where IRIDEX's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 23.60% mean?
IRIDEX (IRIX) has a 5-Year EBITDA Growth Rate of 23.60% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for IRIDEX and its competitors.
Is IRIDEX's 5-Year EBITDA Growth Rate too high?
IRIDEX's current 5-Year EBITDA Growth Rate is 23.60%. Overall, IRIDEX has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRIDEX's 5-Year EBITDA Growth Rate compare to ICCM and LFWD?
IRIDEX's 5-Year EBITDA Growth Rate of 23.60% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for IRIDEX and its competitors. IRIDEX's current 5-Year EBITDA Growth Rate is 23.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRIDEX stock overvalued right now?
Based on GuruFocus' analysis, IRIDEX (IRIX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.70, compared to a current price of $0.88 — trading 48.2% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 23.60%. IRIDEX's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For IRIDEX (IRIX), the current 5-Year EBITDA Growth Rate is 23.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IRIDEX (IRIX) Overvalued in 2026?
Based on GuruFocus' analysis, IRIDEX stock appears to be undervalued.
The current stock price of $0.88 is trading 48.2% below its estimated GF Value™ of $1.70.
GuruFocus considers IRIDEX to be Possible Value Trap.
Key valuation signals for IRIX:
5-Year EBITDA Growth Rate: 23.60%
GF Value™: $1.70 vs. price of $0.88 (48.2% below fair value)
No single metric tells the full story. See the IRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
60GF Score
Get the complete analysis for IRIX
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRIX has been successfully added to your 
